Ticker

6/recent/ticker-posts

Experts Hope Mesothelioma Patients to Be Treated With A New Approach

Malignant mesothelioma patients always needed a new treatment approach from the beginning. And so, researchers devised a new line of treatment known as immunotherapy. But during the course of time, this technique could not prove as effective as the experts thought.


mesothelioma


The technique called immunotherapy was devised for extended survival of malignant mesothelioma patients. But its continuous use ended up making such patients sicker. However, the case was not so initially as the patients are known to have initially derived benefits from its use.

Looking into the above, a team of researchers in the UK (United Kingdom) are known to have explored combining the ongoing treatment with a new experimental drug.

With this line of treatment, experts in the UK hope that this new treatment will support the effectiveness of immunotherapy.

 

Mesothelioma Patients May Get Benefit with New Treatment

Until now, immunotherapy worked quite well against the malignant mesothelioma which falls under a rare type of cancer.

Ever since experts started using the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) later that same year, it started benefiting mesothelioma patients.

It all happened in June 2020 when FDA had approved the use of the drug called Keytruda. And since then loads of patients suffering from one or other type of mesothelioma have been able to get benefit.

But over the passage of time, it was found that he new approach slowly declined the effectiveness as the treatment relied to immune system to target and kill cancer cells.

When such a finding came, the team of researchers from the Institute of Cancer Research in the United Kingdom tried to devise a new line of treatment to extend the lives of such patients.

In the new approach, oncologists started exploring to combine the immunotherapy drugs with a new medication called guadecitabine so as to overcome the risk of resistance.

 

Immunotherapy Combination Gives Positive Results to Mesothelioma Patients

Patients who are diagnosed with mesothelioma are well informed that it is a rare type of cancer which is often fatal. Still, experts continue to find new innovations to handle such a menace.

The recent study conducted in the UK didn't actually include mesothelioma patients. They simply included all those patients diagnosed with different types of cancers and are even treated with the same drugs as the asbestos-related cancer.

As per a report, after such patients received the guadecitabine/pembrolizumab combination, as many as one third patients found their cancer halted in one way or the other.



Also Read: Sarcomatoid Mesothelioma Treatment, Diagnosis Survival and Sub types


Post a Comment

0 Comments